The company is building a clinical network of therapists trained in ketamine-assisted psychotherapy across the United States.
A new clinical network being created across North American will make it easier for patients to access ketamine-assisted psychotherapy (KAP). Field Trip Health’s new KAP Co-Op Program will make its therapeutic centers available for qualified professionals to directly facilitate ketamine therapy for their clients with the support of the company’s trained and experienced clinical medical staff.
Based in Toronto, Canada, Field Trip Health’s mission is to support the creation of a next-generation, sustainable psychedelic medicine industry and to build safe and comfortable spaces to facilitate psychedelic-assisted exploration, transformation, and healing. Currently, the company operates clinics in Toronto, New York, Los Angeles, Chicago, Atlanta, and Houston. Further clinics are slated to open soon in San Diego, San Carlos/San Jose, Seattle, and Washington, DC.
Field Trip Health says it is on track to have 20 clinics open or under construction by December 2021. Each site features at least four treatment rooms, two consultation rooms, and an integration space with pillows, music, art supplies, and more for clients who wish to use this space to relax and reset before leaving the clinic.
The KAP Co-Op Program is open to independently licensed or registered psychotherapists who have already completed training at an approved psychedelic-assisted psychotherapy program provider.
Therapists are required to have a minimum of two years of clinical experience post-licensure in individual and group therapy, with a focus on addressing common and complex mental health issues such as depression, anxiety, and trauma. They are also required to have working knowledge and demonstrated training in evidence-based therapies such as cognitive behavioral therapy, acceptance and commitment therapy, and emotion-focused psychotherapy.
Once a therapist has applied and been approved for the program, they will be granted privileges to Field Trip Health’s KAP-related services at one of the company’s centers. A session is two hours long and it costs $400.
Field Trip Health’s clinical team will support therapists to provide KAP in several ways. They will screen all potential clients to ensure that KAP is safe and appropriate for them and will administer the ketamine to approved clients, typically through intramuscular injection and, in some cases, via a sublingual lozenge. Throughout the session, the clinical team will also assist in monitoring the client in a manner that does not intrude on the therapeutic environment being provided by the therapist.
In addition to expanding its network of psychedelic-assisted therapy sites, Field Trip Health is developing its digital tools ‘Trip’ and ‘Portal’ to provide global access to consciousness expansion therapy and resources. The company also plans to begin Phase 1 human trials evaluating the use of its patent-pending, novel psychedelic molecule FT-104 as a treatment for a variety of central nervous system disorders in Q1 of 2022.